Guangzhou Baiyunshan Pharmaceutical Holdings (600332.SS)

Executive Summary

Guangzhou Baiyunshan Pharmaceutical Holdings is a premier Chinese pharmaceutical conglomerate with a heritage dating back to 1896. As one of the country's largest publicly traded pharma companies (600332.SS), it operates across traditional Chinese medicine (TCM), chemical drugs, and healthcare products. With a market capitalization of approximately $36.6 billion, Baiyunshan leverages its extensive distribution network and strong brand recognition to capture a significant share of China's growing healthcare market. The company's portfolio includes iconic TCM products like Banlangen granules and Huatuo Zaizao pills, which are widely used for influenza and stroke recovery, respectively. Through ongoing R&D, Baiyunshan is also advancing modern pharmaceutical formulations, targeting indications such as vascular dementia and influenza, as evidenced by its clinical pipeline.

Upcoming Catalysts (preview)

• Q3 2026H1 2026 Earnings Release90% success
• Q4 2026NMPA Approval for New TCM Chronic Disease Treatment60% success
• Q1 2027Strategic Overseas Partnership or Acquisition50% success